Meghan Fitzgerald
Known title: DirectorCIK: 0001349297
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Transaction History
| ROIV | ▲ Buy | Grant | 5,054 | $0 | 9/16/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 4,712 | $187K | 9/15/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 400 | $16K | 9/15/2026 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 1,743 | $71K | 9/10/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 20,000 | $176K | 9/8/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 20,000 | $798K | 9/8/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 10,000 | $88K | 6/30/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 10,000 | $349K | 6/30/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| THC | ▼ Sell | Other | 493 | $86K | 5/22/2026 | View on chart |
| ROIV | ▲ Buy | Option Exercise | 70,000 | $616K | 3/26/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 70,000 | $1.9M | 3/26/2026 | View on chart |
| ROIV | ▲ Buy | Grant | 14,524 | $0 | 9/10/2025 | View on chart |
| ROIV | ▼ Sell | Other | 937 | $13K | 9/10/2025 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| THC | ▼ Sell | Other | 573 | $92K | 5/23/2025 | View on chart |
| ROIV | ▼ Sell | Other | 894 | $11K | 9/12/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 16,406 | $0 | 9/10/2024 | View on chart |
| THC | ▼ Sell | Open Market | 20,000 | $2.9M | 8/6/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,261 | $0 | 4/24/2024 | View on chart |
| ROIV | ▼ Sell | Tax Withholding | 83 | $905 | 4/24/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,328 | $0 | 1/19/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 1,269 | $0 | 10/16/2023 | View on chart |
| ROIV | ▲ Buy | Grant | 8,937 | $0 | 9/12/2023 | View on chart |
| ROIV | ▲ Buy | Grant | 1,152 | $0 | 7/3/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| THC | ▲ Buy | Grant | 3,836 | $0 | 5/9/2022 | View on chart |
| THC | ▼ Sell | Open Market | 6,077 | $442K | 9/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.